BROWSE

Related Researcher

Author

Do, Yoonkyung
DC-based Immune System & Immunotherapy (DISNI) Lab
Research Interests
  • Study on various subsets of dendritic cells and their immunological functions

ITEM VIEW & DOWNLOAD

Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells

Cited 18 times inthomson ciCited 21 times inthomson ci
Title
Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells
Author
Do, YoonkyungHegde, VLNagarkatti, PSNagarkatti, M
Keywords
PROTEIN-KINASE-C; COLONY-STIMULATING-FACTOR; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; PHASE-I; SYNGENEIC TUMOR; DOWN-REGULATION; LEUKEMIA-CELLS; LYMPHOCYTES-T; TNF-ALPHA
Issue Date
200409
Publisher
AMER ASSOC CANCER RESEARCH
Citation
CANCER RESEARCH, v.64, no.18, pp.6756 - 6765
Abstract
In this study, we investigated the effect of bryostatin-1 (Bryo-1), an antineoplastic agent, on dendritic cell (DC) maturation, activation, and functions. Murine bone marrow-derived DCs on culture with Bryo-1 alone, Bryo-1 + calcium ionophore (CI), but not CI alone exhibited morphologic changes characteristic of mature DCs and expressed increased levels of CD40, CD80, and CD86. Moreover, Bryo-1 + CI-treated DCs exhibited enhanced antigen-presenting ability to naive and antigen-specific T cells and alloreactive T cells. Bryo-1 + CI-mediated activation of DCs involved protein kinase C (PKC), especially PKC-α, δ, and - ι, and addition of PKC inhibitors impaired their ability to activate T cells. Bryo-1 + CI treatment of DCs did not activate mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase, p38 MAPK, or stress-activated protein kinase/c-Jun NH 2-terminal kinase pathways. Finally, treatment of DCs with Bryo-1 alone and Bryo-1 + CI, but not CI alone, induced nuclear translocation of nuclear factor κB as studied by confocal microscopy. DCs generated from human peripheral blood monocytes or from human cord blood CD34 + hematopoietic stem cells, when cultured with Bryo-1 + CI, also showed maturation and increased T-cell stimulatory activity. Bryo-1 + CI was more potent in inducing maturation and activation of DCs when compared with other agents such as tumor necrosis factor α, lipopolysaccharide, or phorbol 12-myristate 13-acetate + CI. Collectively, the current study shows for the first time that Bryo-1 alone or in combination with CI may promote the maturation of DCs and therefore may be useful in development of DC-based cancer immunotherapy.
URI
Go to Link
DOI
http://dx.doi.org/10.1158/0008-5472.CAN-03-4002
ISSN
0008-5472
Appears in Collections:
SLS_Journal Papers

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show full item record

qr_code

  • mendeley

    citeulike

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

MENU